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A b s t r a c t
Background: Mitoxanthrone (MTX) is a synthetic anthracycline antibiotic that has been used for several years in the treatment 
of patients with primary progressive, secondary progressive, and relapsing remitting multiple sclerosis (MS) who do not respond 
to other drugs. MTX has antineoplastic, immunomodulatory, and antibacterial properties. The most common adverse effects 
of MTX include nausea and vomiting, hair loss, increased risk of urinary and respiratory tract infections, and amenorrhea. 
Less frequent problems include leukopenia, thrombocytopenia, anaemia, and an increase in hepatic enzyme and bilirubin 
levels. Other severe sequelae of MTX treatment are drug cardiotoxicity and a potential to induce leukaemia. Drug toxicity 
results from its affinity to iron ions. The resulting complex strongly induces formation of free oxygen radicals and increases lipid 
peroxidation. Asymptomatic reduction in left ventricular ejection fraction (LVEF) by two-dimensional (2D) echocardiography, 
cardiomyopathy, and congestive heart failure have been observed in patients with MS at a rate of about 2.6–5%. Few studies 
evaluated cardiotoxicity of MTX in MS patients. Most previous studies were performed in small groups of cancer patients and 
cardiac evaluation was limited to physical examination.
Aim: To evaluate the effect of MTX treatment on LVEF by 2D echocardiography.
Methods: We studied 72 MS patients aged 25–63 years who were treated with MTX in 2002–2014. The diagnosis of MS 
was made using the 2001 McDonald criteria updated in 2005. The study group included primary progressive MS in 40 (56%) 
patients, secondary progressive MS in 5 (7%) patients, and relapsing remitting MS in 27 (37%) patients. MTX was administered 
at 12 mg/m2 of body surface area every 3 months (up to the total dose of 140 mg/m2). MTX treatment was initiated in patients 
with no signs of heart failure on physical examination, normal electrocardiogram (ECG), normal LVEF by 2D echocardiogra-
phy, and normal laboratory test findings including complete blood count and hepatic and renal function parameters. Each 
MTX administration was preceded by 2D echocardiography with LVEF measurement, ECG, and physical examination of the 
cardiovascular system. The effect of MTX treatment on LVEF was evaluated by comparing baseline LVEF with LVEF measure-
ments before the last MTX dose. Statistical analysis was performed using the Student t test.
Results: The mean LVEF before administration of the first MTX dose was 65 ± 3.3%. The lowest LVEF at the final 2D echo-
cardiographic examination was 60 ± 2.1%. We did not find a significant LVEF reduction during MTX treatment in MS patients 
compared to baseline values. Severe myocardial dysfunction manifesting with significant LVEF reduction by 2D echocardiog-
raphy or clinical evidence of heart failure was not noted in any patient in the study group.
Conclusions: Our study showed no significant LVEF reduction during MTX monotherapy in MS patients without a history 
of a cardiac disease and with normal echocardiographic findings at baseline. Long-term cardiac effects of MTX require fur-
ther studies.
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INTRODUCTION
Mitoxanthrone (MTX) is a synthetic anthracycline antibiotic, 
an anthraquinone derivative that has antineoplastic, immu-
nomodulatory, and antibacterial properties [1, 2]. In 1987, it 
was licensed for the treatment of leukaemias. It is also used 
in the treatment of breast, prostate, hepatic, ovarian, and 
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gastric cancers. In the clinical practice, a beneficial effect 
of MTX has been observed on a decrease of the number of 
relapses and progression of disability in patients with primary 
progressive, secondary progressive, and relapsing remitting 
multiple sclerosis (MS) who do not respond to the treatment 
with interferon (IFN) b1a and b1b and glatiramer acetate 
[1, 3]. MTX is a small molecules that crosses the blood-brain 
barrier [4]. It affects both proliferating and non-proliferating 
cells. It inhibits topoisomerase II activity, DNA replication, and 
RNA synthesis. MTX reduces T lymphocyte, B lymphocyte, 
and macrophage activity, and decreases antibody production 
[1, 3, 5]. MTX is an inhibitor of antigen presentation, and se-
cretion of INFg, interleukin 2 and tissue necrosis factor a [6]. 
It induces apoptosis of other immunocompetent cells, such as 
T lymphocytes and dendritic cells [7]. Due to poor bioavail-
ability following oral administration, MTX is administered in 
the treatment of MS at a standard dose of 12 mg/m2 of body 
surface area (BSA) every 3 months up to the total dose of 
120–140 mg/m2 [3, 6, 8]. The most common adverse effects of 
MTX include nausea and vomiting, hair loss, increased risk of 
urinary and respiratory tract infections, and amenorrhea. Less 
frequent problems include leukopenia, thrombocytopenia, 
anaemia, and an increase in hepatic enzyme and bilirubin 
levels. Other severe limitations of MTX treatment are drug 
cardiotoxicity and a potential to induce leukaemia [3, 8, 9]. 
Congestive heart failure (HF) develops in about 2.6–5% of 
the treated patients [10]. Toxicity of MTX results from its 
quinone structure which may be reduced to semiquinone, 
releasing a free electron which is transferred to an oxygen 
moiety, initiating the free radical cascade. Cardiac toxicity 
of MTX is related to the presence of abundant amounts of 
lipids in the inner mitochondrial membrane, which bind to 
MTX particles. The drug also shows affinity to iron ions. The 
resulting complex strongly induces formation of free oxygen 
radicals. Few studies evaluated cardiotoxicity of MTX in MS 
patients. The aim of the study was to evaluate the effect of 
MTX treatment on left ventricular ejection fraction (LVEF) by 
two-dimensional (2D) echocardiography.
METHODS
Our study was a retrospective evaluation of 72 patients with 
MS aged 25–63 years who were treated at the Department 
of Neurology, Military Institute of Medicine, Warsaw, in 
2002–2014. Multiple sclerosis was diagnosed based on the 
2001 McDonald criteria updated in 2005 [11]. The study 
group included 72% women and 28% men. The mean age 
was 47 ± 10.64 years (47.9 years in women and 44.6 years 
in men). The study group included 40 (56%) patients with 
primary progressive MS, 5 (7%) patients with secondary pro-
gressive MS, and 27 (37%) patients with relapsing remitting 
MS. Patients were administered MTX in an intravenous infu-
sion at 12 mg/m2 of BSA every 3 months (up to the total dose 
of 140 mg/m2). The patients received 1–5 drug doses. Total 
dose ranged from 18 to 144 mg, mean 65 mg. MTX treat-
ment was initiated in patients with no signs of HF on physical 
examination, normal electrocardiogram (ECG), normal LVEF 
by 2D echocardiography, and normal laboratory test findings 
including complete blood count and hepatic and renal func-
tion parameters. Each MTX administration was preceded by 
2D echocardiography with LVEF measurement, ECG, and 
physical examination of the cardiovascular system. LVEF was 
calculated using the formula: LVEF = 7 / (D + 2.4) × D3, 
where D is the left ventricular diameter. The effect of MTX 
treatment on LVEF was evaluated by comparing baseline 
LVEF with LVEF measurements before the last MTX dose 
at 3–15 months of treatment. The study did not include 
follow-up after termination of MTX therapy. Statistical analysis 
was performed using the Student t test.
RESULTS
The mean LVEF before administration of the first MTX dose 
was 65 ± 3.3% (lowest value 60%, highest value 78%). In the 
study group (n = 72), 2D echocardiography was normal in 
58 (90%) patients and showed minor abnormalities in 7 (10%) 
patients, including left ventricular hypertrophy, interatrial sep-
tal aneurysm, right ventricular dilatation, trace aortic regurgita-
tion, and mild atrioventricular valve insufficiency which were 
not contraindications to MTX therapy (Table 1). The lowest 
LVEF at the final 2D echocardiographic examination was 60% 
and the highest LVEF was 70% (mean 65 ± 2.1%). We did not 
find a significant LVEF reduction during MTX treatment in MS 
patients compared to baseline values (p = 0.083) (Table 2). 
Severe myocardial dysfunction manifesting with significant 
LVEF reduction by 2D echocardiography or clinical evidence 
of HF was not noted in any patient in the study group.
DISCUSSION
Severe limitations of MTX use include drug cardiotoxicity and 
a potential to induce leukaemia [3, 8, 9]. The mechanism of 
these adverse effects has not been fully elucidated. It is prob-
ably related to the ability of the drug to induce formation of 
chelate complexes with iron ions which stimulate formation of 
reactive oxygen species that damage cardiomyocytes [1, 12]. 
Table 1. Echocardiographic findings in multiple sclerosis  
patients selected for mitoxanthrone therapy
Echocardiography Number (%) 
of patients 
Normal 65 (90.28%)
Trace regurgitant jet 3 (4.17%)
Interatrial septal aneurysm 1 (1.39%)
Right ventricular dilatation 1 (1.39%)
Left ventricular hypertrophy 1 (1.39%)
Mild atrioventricular valve insufficiency 1 (1.39%)
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Another possible reason for MTX cardiotoxicity is the pres-
ence of abundant amounts of lipids in the inner mitochondrial 
membrane, which bind to MTX particles [1]. Other reports 
indicated that cardiac toxicity of MTX increases with the drug 
dose [13–15]. These data were obtained in patients who 
received MTX for the treatment of neoplastic disease. Few 
studies evaluated the effect of MTX on the myocardium during 
MTX monotherapy of MS. Single cases of asymptomatic LVEF 
reduction by 2D echocardiography, cardiomyopathy, and con-
gestive HF were reported in MS patients. While symptomatic 
HF develops in about 0.2–0.5% of patients treated with MTX, 
asymptomatic LVEF reduction is 3 times more common [16]. It 
was shown that cardiac toxicity increases with higher infusion 
rate and dose of the drug. It is recommended to administer 
the drug in an intravenous infusion lasting no less than 30 min 
and not to exceed the total dose of 140 mg/m2 of BSA [17]. 
MTX should not be used in patients with LVEF below 50% 
[3, 18]. The Food and Drug Administration recommends 
echocardiography with evaluation of LVEF before each MTX 
administration. A decrease in LVEF by more than 10 percent-
age points compared to baseline or below 50% is an indication 
to withdraw treatment [3]. In addition to cardiomyopathy 
and congestive HF, other manifestations of cardiac toxicity 
of MTX include tachycardia and cardiac arrhythmia [1]. The 
authors of the recommendations of the National Team of 
Cardiologic and Oncologic Supervision on cardiac safety of 
breast cancer patients described morphological and functional 
myocardial changes due to anthracycline administration as 
chemotherapy-related cardiac dysfunction (CRCD) type I. 
They also discussed three possible types of cardiac dysfunction 
resulting from the use of this class of drugs: perimyocarditis, 
early-onset HF developing during oncological treatment or 
soon after its termination, and late-onset HF manifesting 
several years after oncological treatment [19].
In our study, we did not find a significant reduction in 
LVEF by 2D echocardiography measured before the last dose 
of the drug compared to baseline pretreatment values. We 
also did not find any case of LVEF reduction below 50% or 
by 10 percentage points compared to baseline. It should be 
noted, however, that LVEF measured by 2D echocardiogra-
phy is not a sensitive method, with differences of up to 10% 
noted between subsequent measurements without significant 
cardiac damage. A more sensitive method to monitor cardio-
myocyte damage is troponin level measurement. The authors 
of the recommendations of the National Team of Cardiologic 
and Oncologic Supervision advise troponin measurement 
soon after the infusion is terminated, at 24 h and 72 h, and 
at 1 month after anthracycline administration [19]. Patients 
in our study did not report chest pain or palpitation, and 
we noted no case of HF symptoms during MTX treatment. 
Similar conclusions were arrived at by Zingler et al. [20] who 
evaluated LVEF by echocardiography in 73 patients with MS 
and found no significant LVEF reduction during treatment. 
In that study group, however, 1 case of atrial fibrillation epi-
sode was noted after the second MTX dose in a patients with 
hypertension and previous myocardial infarction. In another 
study by Ghalie et al. [21] in a much larger population of 
1378 patients treated with MTX, symptoms of congestive HF 
developed in only 2 cases, and asymptomatic LVEF reduction 
below 50% was noted in 2.18% of patients, more frequently 
with higher drug doses above 100 mg/m2 of BSA [21–23]. In 
another study in 93 patients, asymptomatic LVEF reduction 
resulted in treatment termination in 5 patients. In 4 of these 
patients, LVEF normalised within few months. In 1 patient, 
myocardial infarction occurred at 18 months after treatment 
termination [9]. Deobuverie et al. [1] noted 2 cases of LVEF 
reduction below 45% in a group of 307 patients with primary 
progressive and relapsing remitting MS treated with MTX. 
Fewer data are available on long-term cardiac effects of MTX 
treatment. Goffette et al. [10] described 3 patients in whom 
congestive HF developed at 24, 29, and 60 months after ad-
ministration of the last MTX dose. Two of these patients were 
previously treated with cyclophosphamide which might have 
increased the cardiotoxic effect of MTX [10]. During 3 years of 
follow-up, Hartung et al. [8] reported 4 cases of asymptomatic 
LVEF reduction in a group of 196 patients, with no case of 
congestive HF resulting from MTX treatment [8]. 
CONCLUSIONS
In summary, previous studies indicate that the risk of cardiac 
damage during MTX monotherapy in MS patients without 
a history of cardiac disease and with normal baseline echo-
cardiography is low. Further studies are required to investigate 
long-term cardiac effects of MTX. Cardiac damage manifesting 
with LVEF reduction may occur years after treatment comple-
tion. The utility of cardiac monitoring using more sensitive 
methods such as high-sensitivity cardiac troponins or cardiac 
magnetic resonance imaging should be considered [19].
Conflict of interest: none declared
Table 2. Left ventricular ejection fraction (LVEF) by two-dimensional echocardiography before and after mitoxanthrone treatment 
(Student t test)
Measurement timing Mean LVEF Standard deviation Student t test P
Before treatment 65.3% 3.3% 1.76 0.083
After treatment 64.7% 2.1%
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Wpływ leczenia mitoksantronem na serce  
u chorych na stwardnienie rozsiane
Żanna Pastuszak, Kazimierz Tomczykiewicz, Renata Piusińska-Macoch, Adam Stępień
Wojskowy Instytut Medyczny, Warszawa
S t r e s z c z e n i e
Wstęp: Mitoksantron (MTX) jest syntetycznym antybiotykiem antracyklinowym stosowanym od kilku lat w leczeniu chorych 
z postacią pierwotnie i wtórnie postępującą oraz rzutowo-remisyjną stwardnienia rozsianego (MS), nieodpowiadających na 
terapię innymi lekami. Wykazuje działanie przeciwnowotworowe, immunomodulujące i przeciwbakteryjne. Najczęstszymi 
działaniami niepożądanymi stosowania MTX są nudności i wymioty, wypadanie włosów, zwiększone ryzyko infekcji dróg 
moczowych i oddechowych, brak miesiączki. Rzadziej występują: leukopenia, trombocytopenia, niedokrwistość, wzrost 
stężenia enzymów wątrobowych i bilirubiny. Innym groźnym następstwem stosowania MTX jest kardiotoksyczność leku oraz 
możliwość wywołania białaczki. Toksyczność leku wynika z jego powinowactwa do jonów żelaza. Kompleks ten ma silne 
właściwości tworzenia rodników tlenowych, a także nasilenia peroksydacji lipidów. U chorych na MS obserwowano bezob-
jawowe klinicznie obniżenie frakcji wyrzutowej lewej komory (LVEF) w dwuwymiarowym badaniu echokardiograficznym 
(ECHO 2D), kardiomiopatię oraz zastoinową niewydolność serca, występującą z częstością 2,6–5%. W niewielu badaniach 
oceniono kardiotoksyczność MTX u chorych na MS. Większość dotychczasowych opracowań opiera się na małych grupach 
chorych leczonych onkologicznie i na ocenie funkcjonowania serca w badaniu przedmiotowym. 
Cel: Celem niniejszej pracy była ocena wpływu leczenia MTX na LVEF określonej w ECHO 2D.
Metody: Badaniem objęto 72 pacjentów z MS w wieku 25–63 lat leczonych MTX w latach 2002–2014. Stwardnienie rozsiane 
rozpoznano na podstawie kryteriów McDonalda z 2001 r., uaktualnionych w 2005 r. W grupie z postacią pierwotnie postępującą 
było 40 (56%) osób, z wtórnie postępującą — 5 (7%) chorych oraz rzutowo-remisyjną MS — 27 (37%) pacjentów. Chorym 
podawano MTX w dawce 12 mg/m2 powierzchni ciała co 3 miesiące (do maksymalnej łącznej dawki 140 mg/m2). Warunkami 
włączenia pacjenta do leczenia MTX były: brak objawów niewydolności serca w badaniu przedmiotowym i prawidłowy zapis 
elektrokardiograficzny, prawidłowy wynik ECHO 2D z oceną LVEF, prawidłowe wyniki badań morfologicznych i biochemicznych 
krwi, w tym wartości enzymów wątrobowych i parametrów nerkowych. Przed każdorazowym podaniem MTX wykonywano 
ECHO 2D z pomiarem LVEF i elektrokardiogram oraz oceniano funkcjonowanie układu sercowo-naczyniowego w badaniu 
przedmiotowym. Wpływ leczenia MTX na wartość LVEF oceniano, porównując wartości LVEF przed rozpoczęciem terapii 
w stosunku do pomiaru wykonanego przed podaniem ostatniej dawki MTX. W analizie danych posłużono się testem t-Studenta. 
Wyniki: W wyjściowym ECHO 2D serca u chorych na MS wykonanym przed podaniem pierwszej dawki MTX średnia wartość 
LVEF wynosiła 65 ± 3,3%. Najniższa wartość LVEF w końcowym ECHO 2D wynosiła 60 ± 2,1%. Nie wykazano istotnego 
statystycznie obniżenia LVEF w czasie leczenia MTX chorych na MS w stosunku do wartości sprzed terapii. W badanej grupie 
chorych nie odnotowano ciężkiego uszkodzenia mięśnia sercowego objawiającego się znacznym obniżeniem LVEF w ECHO 2D 
lub niewydolnością serca w badaniu przedmiotowym.
Wnioski: Wyniki badań nie wykazały istotnego obniżenia LVEF w trakcie monoterapii MTX u chorych na MS, nieobciążo-
nych kardiologicznie, z prawidłowym wynikiem wstępnego badania echokardiograficznego. Dalszych badań wymaga ocena 
długoterminowego wpływu MTX na mięsień sercowy.
Słowa kluczowe: mitoksantron, badanie echokardiograficzne, stwardnienie rozsiane
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